Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 31, 2014 - Issue 6
Submit an article Journal homepage
512
Views
4
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES Immune Thrombocytopenia

Rituximab Efficacy in the Treatment of Children with Chronic Immune Thrombocytopenic Purpura

Sh. AnsariDepartment of Hematology and Oncology, Ali-Asghar Hospital, Iran University of Medical Science, Tehran, Iran
,
T. RostamiDepartment of Hematology and Oncology, Ali-Asghar Hospital, Iran University of Medical Science, Tehran, IranCorrespondence[email protected]
,
S. YousefianDepartment of Hematology and Oncology, Ali-Asghar Hospital, Iran University of Medical Science, Tehran, Iran
,
A. KiumarsiDepartment of Hematology and Oncology, Ali-Asghar Hospital, Iran University of Medical Science, Tehran, Iran
,
G. Miri-AliabadChildren and Adolescent Health Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
&
T. RamimSina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran
Pages 555-562 | Received 14 Feb 2014, Accepted 24 May 2014, Published online: 09 Jul 2014

REFERENCES

  • Ferrara M, Bertocco F, Ferrara D, Capozzi L. Chronic immune thrombocytopenic purpura in childhood: pathogenetic mechanisms and management. Hematology. 2012;17(6):363–366.
  • British Commitee for Standards in Haematology. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120:574–596.
  • Liu XG, Hou M. Immmmune thrombocytopenia and B-cell-activating factor/a proliferation-inducing ligand. Semin Hematol. 2013;50(Suppl 1):S89–99. doi: 10.1053/j.seminhematol. 2013.03.021.
  • Nishimoto T, Kuwana M. CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin Hematol. 2013;50(Suppl 1):S43–S49. doi: 10.1053/j.seminhematol. 2013.03.018.
  • Provan D, Stasi R, Newland AC, International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186. doi: 10.1182/blood-2009-06-225565. Epub 2009 Oct 21.
  • Rodeghiero F, Stasi R, Gernsheimer T, Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi: 10.1182/blood-2008-07-162503. Epub 2008 Nov 12.
  • Vianelli N, Galli M, de Vivo A, Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005;90:72–77.
  • Bengston KL, Skinner MA, Ware RE. Successful use of anti-CD20 (Rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. J Pediatr. 2003;143:670–673.
  • Taube T, Schmid H, Reinhard H, Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica. 2005;90:281–283.
  • Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother. 2004;58:299–309.
  • Zaja F, Iacona I, Masolini P, B-cell depletion with rituximab as treatment for immune hemolytic anemia and thrombocytopenia. Haematologica. 2002;87:189–195.
  • Zecca M, Nobili B, Ramenghi U, Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101:3857–3861.
  • Aggarwal A, Catlett JP. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura. South Med J. 2002;95:1209–1212.
  • Ghanima W1, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012;120(5):960–969. doi: 10.1182/blood-2011-12-309153. Epub 2012 Jun 26.
  • Taube T, von Stackelberg A, Schulte-Overberg U, Chronic mmune thrombocytopentic purpura in children: Assessment of rituximab treatment. J Pediatr 2006;148:42.
  • Mueller BU, Bennett CM, Feldman HA, One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer. 2009;52:259–262.
  • Dierickx D, Verhoef G, Van Hoof A, Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med. 2009;266(5):484–491.
  • Peñalver FJ, Jiménez-Yuste V, Almagro M, Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol. 2006;85(6):400–406.
  • Ling Y, Qian X, Cao X. Combination therapy of rituximab and corticosteroids for patients with refractory chronic immune thrombocytopenic purpura: report of two cases. Contemp Oncol (Pozn). 2013;17(2):222–224.
  • Wang J, Wiley JM, Luddy R, Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005;146:217–221.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.